This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): somatropin depot
Description: Nutropin Depot is a long-acting Nutropin formulation that reduces the frequency of injections by encapsulating the drug in biodegradable microspheres.
Nutropin, Nutropin AQ, Nutropin Depot, and Protropin are Genentech’s four recombinant human growth hormone/somatropin formulations indicated for the treatment of short stature.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Genentech partnered with Alkermes in January 1995 to use Alkermes microsphere technology to develop a long-acting formulation of Nutropin.
Genentech had partnered with both Schwarz Pharma and Sumitomo to market Nutropin Depot outside the U.S., but later re-acquired rights from both of these partners.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
Partners: Alkermes plc
Nutropin Depot News
Pink Sheet Nutropin Depot discontinued
Additional information available to subscribers only: